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Abstract
Currently available information from clinical trials and open-label
extensions suggest that abatacept is a good alternative to other
biologicals in rheumatoid arthritis. Although at first glance the
efficacy of all biologicals appears to be the same, in routine
practice one might expect there to be differences in effectiveness,
safety profiles and specific patient-centered outcomes. These
patient-centered outcomes, as well as safety, deserve further
attention in follow-up registries, but also in prospective studies, if
we are to optimize patient care. After failing a first tumor necrosis
factor blocker, patients have several treatment options - starting a
second tumor necrosis factor blocker, or rituximab or abatacept -
but no formal randomized studies are available to indicate what is
the optimal strategy. Potential differences between treatments with
biologicals with different modes of action in very early disease also
require more study. It is difficult to determine how co-stimulation
blockade will influence Crohn’s disease or psoriatic arthritis as well
as other diseases characterized by a specific role of the adaptive
immune system, such as systemic lupus erythematosus and
multiple sclerosis. It is clear, however, that every additional
targeted therapy creates new opportunities for treatment in many
different patient populations.
Introduction
The past decade has witnessed important progress in our
understanding of inflammatory rheumatic diseases. Together
with new technological advances, this has led to the
development, clinical evaluation and routine use of several
biological agents. In rheumatoid arthritis (RA), especially, this
has resulted in such an improvement in treatment efficacy
that numbers of patients in the Western world who are in
need of alternative therapeutic options and who are ready to
participate in novel clinical trials are dwindling [1]. Several
anticytokine therapies, mainly tumor necrosis factor (TNF)
blockers and, to a lesser extent, an interleukin-1 receptor
antagonist, have successfully been brought to market; TNF
blockers have also found approved indications in ankylosing
spondylitis and psoriatic arthritis [2]. More recently, rituximab
- the first commercialized anti-B-cell therapy - was introduced
for treatment of RA. Compared with the TNF blockers,
rituximab has a different treatment schedule (intermittent) and
a different response profile, characterized by more gradual
onset of beneficial effect, beginning only a few months after
infusion. Additional data regarding the optimal timing of re-
treatment are needed, and there remain unanswered ques-
tions regarding the long-term safety and risks associated with
use of other biologicals after rituximab has failed [3,4]. In
systemic lupus erythematosus (classically considered a B-cell-
driven disease), B-cell directed therapies are being trialled,
and the first promising clinical results have been published [5].
B-cell targeted therapies are also being tested in other
systemic diseases, such as primary Sjögren’s syndrome [6].
Although initial attempts to target the T cell were not
particularly successful [7], co-stimulation blockade is very
promising in the treatment of several diseases that are driven
by an activated adaptive immune system. Co-stimulation
blockade was first clinically tested in the treatment of psoriasis
[8], but patients with RA were the first to benefit from the
advent of abatacept, which is the first co-stimulation blocker
[9,10]. Experience with abatacept in RA is growing thanks to
open-label extensions of clinical trials [11], but published data
from routine practice and patient registries are currently
lacking. Trials of abatacept in systemic lupus erythematosus,
psoriatic arthritis and Crohn’s disease are underway.
Biologicals are often compared solely based on their level of
efficacy in RA, by measuring Disease Activity Score and
American College of Rheumatology (ACR) responses at fixed
time points, without considering differences in mechanisms of
action, in efficacy and safety profiles, and in administration, or
patient preferences and patient reported outcomes. A
biological is a biological. However, in recent years we have
learned that efalizumab [12] is effective in plaque psoriasis
but not in psoriatic arthritis, that etanercept is effective in RA
and spondyloarthropathy but not in Crohn’s disease [13], and
that etanercept might induce sarcoidosis [14]. From these
examples, it is clear that the different modes of action of
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individual biologicals have important implications for their use
in routine clinicial practice.
The need for biologicals with a different
mode of action in rheumatoid arthritis
TNF blockers have altered the clinical evolution of many
previously refractory patients, but based on findings from
registries and cohort studies it is clear that many patients still
exhibit insufficient response, lose their initial response, or
have to stop treatment because of specific side effects. Until
now, in case of failure of a TNF blocker, a common strategy
has been to try a second TNF blocker. However, careful
analysis of patient registries shows that if a first TNF blocker
is discontinued for efficacy or safety reasons, then the reason
for failure of a second TNF blocker is likely to be the same as
that for the first anti-TNF treatment [15]. In a recent Swiss
observational study [16], it was suggested that a drug with a
different mechanism of action, such as rituximab, has greater
potential benefit in this setting, but a corroborating
randomized trial is lacking. Although the increasing number of
therapeutic options is good news for patients, the rheuma-
tology community is increasingly confronted with the dilemma
of which treatment to use in which situation and in which
order. The question also arises of how to monitor and
evaluate these agents in routine practice.
With respect to general efficacy, no major differences are
expected based on the findings of reported clinical trials. (The
ATTAIN [Abatacept Trial in Treatment of Anti-TNF
INadequate responders] [10] and REFLEX [Randomized
Evaluation of Long-Term Efficacy of Rituximab] [17] trials
reported similar ACR responses for abatacept and rituximab,
respectively.) However, head to head clinical trials comparing
different biologicals are lacking. The only currently available
blinded randomized trial was not powered to identify a
difference between abatacept and infliximab [18], but it
confirmed the existence of small differences in efficacy
profiles and safety, suggesting that not all biologicals are the
same. Differences in clinical effectiveness are to be expected
when these agents are incorporated in different therapeutic
strategies and administered to patients with different disease
characteristics, risk profiles, and co-morbidities. Also, patient
preferences are increasingly expected to play a role in
decision making in the future. Finally, the quality of care
programs in which these highly effective drugs are to be used
could be at least as important as their intrinsic level of efficacy.
The focus of this review is the importance of high-quality care
in RA and how current and future therapeutic options will fulfil
the changing needs of patients, placing special emphasis on
co-stimulation blockade. Our expectations from new
treatments can be summarized as a combination of good
efficacy and effectiveness, short-term and long-term safety,
and improvement in functionality and quality of life, and all of
this at an acceptable cost and for as many patients as
possible.
Efficacy and effectiveness of treatment for
rheumatoid arthritis with co-stimulation
blockade
The efficacy of abatacept has been demonstrated in large,
properly designed trials in patients refractory to methotrexate
[9] and to anti-TNF treatment [10]. Comparison of efficacy
between abatacept and other biologicals is not possible
because no good head to head comparisons are available,
and the currently reported differences in efficacy between
biologicals are mainly accounted for by the previous
refractory state of patients, specific patient characteristics
and specific co-morbidities.
In ATTAIN 25% of patients were rheumatoid factor (RF)
negative, and these patients’ responses to abatacept
treatment were no different from those of RF-positive
patients. Not many RF-negative patients have been evaluated
in rituximab trials, but in a recent study conducted by Popa
and coworkers [19], after 7 years follow up four out of five
RF-negative patients were found to be nonresponders. The
impact of patient characteristics on treatment efficacy needs
to be analyzed more systematically in future studies,
especially in registries.
Effectiveness in daily practice might differ between bio-
logicals because of their different response profiles (speed
of response, stability of response, and so on). TNF blockers,
especially infliximab, have a very rapid effect (which is in the
interests of patients) but after a while the response
sometimes diminishes, and questions arise regarding dosing
and treatment frequency, especially for infliximab [20]. A
flare of arthritis in a patient receiving infliximab a few days
before a newly scheduled infusion is not appreciated and
might influence the effectiveness of treatment. The lack of
information in rituximab-treated patients regarding the
optimal timing of retreatment led to the requirement for a
flare (defined by a rise in the Disease Activity Score above
3.2) in the Belgian reimbursement criteria for retreatment.
Having to wait for a flare before retreatment is allowed can
hardly be considered patient friendly.
On the other hand, continuous monthly dosing of abatacept
is apparently associated with a stable response, and the
patient dropout rates from the extension trials are rather low
(high retention rates) [21]. Stable disease control might be a
patient-preferred outcome that requires more study in the
future. In certain respects the response profile of TNF
blockers resembles the effect of corticosteroids, with rapid
onset but also rapid loss of effect as soon as treatment is
interrupted, which is in contrast to the gradual but more long-
lasting effect of B-cell-depleting therapies or co-stimulation
blockade. Our experience with abatacept is that it elicits a
very stable response, and a flare is rarely seen even when an
infusion is postponed for infection or surgery. This also
suggests that in future studies the infusion interval for long-
term treatment should be formally determined.Page 3 of 5
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One might argue that co-stimulation blockade is not as fast-
acting as TNF blockade. On the other hand, starting a
bridging therapy with a short course of steroids together
with abatacept is a cheap and effective strategy to
overcome this temporary disadvantage, provided that
steroids do not influence the efficacy of co-stimulation
blockade. Also, when analyzing in detail the speed of
response to abatacept, one may observe a statistically
significant effect in certain patient outcomes (such as
fatigue) even after 4 weeks [22], which might positively
influence patient adherence to therapy.
The specific mechanism of action of co-stimulation blockade,
being more upstream in the immunological cascade as
compared with TNF blockade, could theoretically lead to an
even more pronounced effect when the agent is used very
early in a disease. Post-hoc subgroup analyses of AIM have
demonstrated greater remission rates in patients with early
disease (<2 years) compared with longer standing disease
(>10 years) [23]. The results of a trial of abatacept in early
RA are expected at the end of 2008.
In addition, a formal trial studying the effect of discontinuing
treatment once remission is achieved or after a certain period
of time might be interesting, in the light of the different
mechanisms of action of co-stimulation blockers as com-
pared with TNF-blocking agents. A recent trial in undiffer-
entiated arthritis with poor prognosis patients (namely, those
positive for cyclic citrullinated protein) failed to identify an
effect of a short course of anti-TNF treatment in delaying the
onset of RA (in terms of fulfilling ACR criteria) [24]. In
contrast, a similar explorative study of abatacept indicated
that this agent appears able to delay the onset of RA to some
extent [25]; this needs further investigation.
The first and most impressive message from the trials of TNF
blockade was the complete arrest of radiographic progres-
sion, which had never previously been observed with any RA
treatment. Data on abatacept indicate a decrease in radio-
graphic progression during the first year, without complete
arrest but with a further decrease in year 2 [26], illustrating a
different efficacy profile as compared with TNF blockers. This
is an important finding with clinical implications for future
treatment decisions in routine practice. However, in view of
the more gradual effect of abatacept, in clinical practice many
rheumatologists might add a short bridging therapy with
steroids, which could have a major impact on the kinetics of
response and, therefore, future radiographic progression,
especially in early RA. Moreover, we must await data on
radiographic progression in the early RA abatacept trial,
because these might reveal differences from findings in
established RA. Recent experimental findings suggest a
specific effect of cytotoxic T-lymphocyte antigen 4 on bone,
independent from TNF-α; it would be interesting to
investigate this in the clinical setting, given the possible
implications for long-term disease control [27].
Theoretically, one could consider combining different target-
ed therapies in order to achieve a better response. However,
combinations of different biologicals, such as TNF blockers
and interleukin-1 receptor antagonists, do not appear to
increase efficacy [28] and result in more side effects, as is the
case when abatacept is combined with TNF blockade [29].
Improvement in functionality and quality of
life with co-stimulation blockade in patients
with rheumatoid arthritis
One might expect that all improvements in disease activity
might be associated with improved functionality and quality of
life, and that, as such, all biologicals would have similar
effects. This might be true to some extent, because similar
improvements in 36-item Short Form are found for many
agents [22,30]. An important issue is whether measures such
as 36-item Short Form are sensitive enough to detect
specific and subtle differences between biologicals in
patient-centered outcomes. Patient-centered outcomes might
be influenced by the stability of disease control, the route of
administration (subcutaneous versus intravenous, length of
perfusion time), risk for infusion reactions (up to 30% in
rituximab trials with need for pretreatment versus a few
percent in abatacept trials), or perhaps other factors of impor-
tance to patients that need more study. An example of an
issue that should be studied in greater detail is sleep. TNF
blockade might have a direct central effect on sleep [31,32].
Steroids are known for their central stimulatory effect. The
first studies with abatacept suggest a beneficial effect on
sleep [33]. More detailed studies specifically comparing
different treatment options head to head with respect to such
specific patient-centered outcomes would be welcome in the
future because of their relevance to daily care.
Safety of co-stimulation blockade and
implications for daily practice in patients with
rheumatoid arthritis
A safety update on abatacept [34] was recently reported and
suggested a different safety profile as compared with inflixi-
mab and rituximab regarding infusion reactions, which might
influence patients’ preferences and improve treatment
effectiveness in the long run.
The lack of de novo development of antinuclear antibodies
and DNA antibodies with abatacept, in contrast to TNF
blockers [18], certainly deserves further attention and might
suggest a role for abatacept (or rituximab) in patients who
develop a clinical picture with newly occurring autoimmune
features, rather than switching to a second or third TNF
blocker. One might consider treating patients with heart
failure preferentially with abatacept instead of a TNF blocker,
and patients with a history of or an active associated B-cell
lymphoma might be good candidates for anti-B-cell therapy.
Increased infection rates have been reported with all bio-
logicals, but rates are difficult to compare between drugs
Available online http://arthritis-research.com/supplements/10/S1/S4because there are no sufficient head to head comparisons.
Nevertheless, apart from different patient characteristics and
possible co-morbidities, the treatment choice as such might
have an influence on infection rates, as is suggested by the
ATTEST (Abatacept or infliximab versus placebo, a Trial for
Tolerability, Efficacy and Safety in Treating RA) data [18] and
by the findings of a recent meta-analysis that compared
anakinra with abatacept and rituximab [35]. All of these
findings might play roles in future therapeutic decisions in
specific circumstances. The different mode of action of
abatacept relative to TNF-blockade means that the former
has a lesser impact on natural mechanisms of defense
against tuberculosis [18] - a finding that has received support
from a recent animal model study [36]; this property might
have a bearing on future decision making.
Little is known about differences in immune profiles after
long-term treatment with specific biologicals. Long-term rituxi-
mab treatment appears to be associated with some persist-
ing decline in immune globulin titers and a certain degree of
lasting B-cell depletion [19]. The clinical relevance of these
findings requires further study. Reports on immune states after
long-term abatacept treatment are not available, but based on
findings reported to date no cell depletion or decrease in
immunoglobulin levels are expected with this agent.
In summary, safety profiles appear to differ between
biologicals. Together with the pretreatment evaluation of
specific risk factors, these differences might influence treat-
ment choices in daily practice.
Conclusion
Newer drugs with different modes of action, such as
rituximab and abatacept, might be attractive alternatives in
patients refractory to a TNF blocker. While at first glance
efficacy of all drugs might look the same, different efficacy
(speed and stability of response) and safety (infection rates,
infusion reactions) profiles are observed. Also, effectiveness
in daily practice might differ as a result of patient preferences.
Further study is needed in daily practice to compare different
treatment strategies, focussing on global effectiveness.
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